Date: 14 Sep 2012
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
▴ Perospirone is an atypical antipsychotic agent for the treatment of schizophrenia. Its primary mode of action is through antagonism of serotonin 5-HT2A and dopamine D2 receptors.
▴ An 8-week course of oral perospirone 8 to 48 mg/day displayed efficacy in up to 75% of patients with schizophrenia participating in phase II and phase III trials. The onset of action of the drug was about 2 weeks.
▴ Perospirone was effective against positive, negative and general symptoms in patients with schizophrenia, as assessed with standard rating scales (Brief Psychiatric Rating Scale, Positive and Negative Symptom Scale).
▴ Compared with haloperidol 2 to 12 mg/day, perospirone 8 to 48 mg/day was significantly more effective against negative symptoms and tended to be more effective against general symptoms and most positive symptoms in a trial in 145 patients with schizophrenia. Perospirone had efficacy similar to that of mosapramine 50 to 300 mg/day in a comparative phase III trial in 159 patients.
▴ Extrapyramidal symptoms (EPS) tended to occur less often and were generally milder with perospirone than with haloperidol or mosapramine.
Lehman AF. Managing schizophrenia: interventions and outcomes. Dis Manage Health Outcomes 1997 Jun; 1: 286–95CrossRef
Emsley RA. Role of newer atypical antipsychotics in the management of treatment-resistant schizophrenia. CNS Drugs 2000; 13(6): 409–20CrossRef
Matsubara R, Hirabayashi Y, Narita H, et al. Clinical evaluation of perospirone hydrochloride (SM-9018) in fine granule form in the treatment of schizophrenic patients [abstract]. Int J Neuropsychopharmacol 2000 Jul; 3 Suppl. 1: 139
Tojima R, Ohno Y, Ishibashi T, et al. Effects of perospirone (SM-9018), a novel 5-HT2 and D2 antagonist, on human D2 and D4 receptors in CHO cells [abstract]. Jpn J Pharmacol 1997; 73 Suppl. I: 176
Saito A, Nishimura T, Fukushima M, et al. Pharmaco-EEG study of SM-9018, a D2 and 5-HT2 antagonist in healthy volunteers [abstract]. Psychiatry Res Neuroimaging 1997 Feb 7; 68: 173–4CrossRef
Inanaga K, Irie S, Urae A, et al. Phase I study of perospirone HCl (SM-9018) [in Japanese]. Kiso to Rinsho 1997; 31(6): 2113–57
Mizuno Y, Kanamaru H, Nakatsuka I, et al. Effect of food on the disposition of SM-9018 in cynomolgus monkeys [in Japanese]. Kiso to Rinsho 1997; 31(2): 821–51
Mizuno Y et al. Disposition of SM-9018 after single oral administration to rats and protein binding to serum of human and animals [in Japanese]. Kiso to Rinsho 1997; 31(2): 543–68
Mizuno Y, Kanamaru H, Nakatsuka I, et al. Transfer of SM-9018 to fetus and milk in rats [in Japanese]. Kiso to Rinsho 1997; 31(2): 755–88
Ishibashi T, Ohno Y, Tokuda Y, et al. CNS pharmacological actions of the major metabolites of perospirone hydrochloride [in Japanese]. Kiso to Rinsho 1997; 31(2): 893–902
Murasaki M, Koyama T, Machiyama Y, et al. Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: a comparative double-blind study with haloperidol [in Japanese]. Rinsho Hyoka 1997; 24(2–3): 159–205
Kudo Y, Nakajima T, Saito M, et al. Clinical evaluation of a serotonin-2 and dopamine-2 receptor antagonist (SDA), perospirone HCl on schizophrenia: a comparative double-blind study with mosapramine HCl [in Japanese]. Rinsho Hyoka 1997; 24(2–3): 207–48
Murasaki M, Koyama T, Machiyama Y, et al. Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: late-phase II study [in Japanese]. Rinsho Hyoka 1997; 31(6): 2181–206
Murasaki M, Yamashita I, Machiyama Y, et al. Early phase 2 study of a new antipsychotic, perospirone HCl (SM-9018), on schizophrenia [in Japanese]. Kiso to Rinsho 1997; 31(6): 2159–79
Murasaki M, Koyama T, Machiyama Y, et al. Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: a study of long-term administration [in Japanese]. Kiso to Rinsho 1997; 31(6): 2207–30
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., rev. Washington, DC: American Psychiatric Association, 1987
World Health Organization. Manual of the international statistical classification of diseases, injuries, and causes of death, 9th revision. v. l. Grneva: WHO, 1977
World Health Organization. International statistical classification of diseases and related health problems, 10th revision. v. 1. Geneva: WHO, 1992
Lader M. Rating scales in schizophrenia: a review of their usefulness for assessing atypical antipsychotics. CNS Drugs 2000; 14(1): 23–32CrossRef
Volume 15, Issue 4 , pp 329-337
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors